Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • JAK
    (5)
  • Tyrosine Kinases
    (2)
  • IFNAR
    (1)
  • Interleukin
    (1)
  • STAT
    (1)
  • Others
    (2)
TargetMol | Tags By ResearchField
  • Inflammation
    (3)
  • Cancer
    (2)
  • Immune System
    (1)
Filter
Search Result
Results for "

jak1-dependent

" in TargetMol Product Catalog.
  • Inhibitors & Agonists
    5
    TargetMol | All_Pathways
Oclacitinib maleate
PF-03394197 maleate, PF-03394197
T69141640292-55-2
Oclacitinib maleate (PF-03394197 maleate) is a novel inhibitor of JAK family members, with IC50 values ranging from 10 to 99 nM, and JAK1-dependent cytokines, with IC50 ranging from 36 to 249 nM, while not inhibiting a panel of 38 non-JAK kinases.
  • $33
In Stock
Size
QTY
Delgocitinib
JTE-052, Corectim(Delgocitinib)
T150961263774-59-9
Delgocitinib (JTE-052) is a JAK inhibitor and a specific JAK1/2/3/Tyk2 inhibitor (IC50=2.6-58 nM) that blocks multiple cytokine signaling pathways and inhibits pruritus, used for research on inflammatory and autoimmune diseases.
  • $172
In Stock
Size
QTY
JAK3-IN-1
T156071805787-93-2
JAK3-IN-1 is an orally active, selective and potent JAK3 inhibitor that can be used to study immune system diseases.
  • $228
6-8 weeks
Size
QTY
VVD-118313
T623612875046-27-6
VVD-118313 (compound 5a), a potent, selective JAK1 inhibitor, targets an isoform-restricted allosteric cysteine to inhibit JAK1-dependent trans-phosphorylation and cytokine signaling. This compound is utilized in cancer research [1].
  • $3,120
3-6 months
Size
QTY
Upadacitinib tartrate
ABT-494, ABT494, ABT 494
T7503L1607431-21-9
Upadacitinib is a potent and selective JAK inhibitor. Upadacitinib is approximately 74 fold selective for Jak1 over Jak2 in cellular assays dependent on specific, relevant cytokines. Upadacitinib demonstrates efficacy in rat arthritis models.
  • $1,970
1-2 weeks
Size
QTY